Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort.


Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
01 01 2021
Historique:
accepted: 18 03 2020
pubmed: 3 4 2020
medline: 1 9 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

To examine the role of disease activity on organ damage over 5 years in patients with active systemic lupus erythematosus (SLE) despite standard of care. This analysis of the University of Toronto Lupus Clinic cohort assessed organ damage [measured by Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] in patients with active SLE [SLE Disease Activity Index 2000 (SLEDAI-2K) ≥ 6], using Cox proportional time-independent hazard models. Subgroup analyses were conducted in patients with SLEDAI-2K 6 or 7, 8 or 9, and ≥ 10 at baseline, and in the overall study population by steroid dose at study entry (< 7.5 vs ≥ 7.5 mg/day). Among the overall study population (n = 649), SDI progression was observed in 209 (32.2%) patients over the 5-year follow-up period. Mean SDI change in patients with a score > 0 was generally consistent across all SLEDAI-2K subgroups. Multivariable analyses identified age at study start (HR 1.03, Patients within the higher SLEDAI-2K subgroups at study entry or receiving high doses of steroids were more likely to have organ damage progression.

Identifiants

pubmed: 32238510
pii: jrheum.190259
doi: 10.3899/jrheum.190259
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-73

Auteurs

Murray B Urowitz (MB)

M.B. Urowitz, MD, D.D. Gladman, MD, D. Ibañez, MSc, J. Su, MSc, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; m.urowitz@utoronto.ca.

Dafna D Gladman (DD)

M.B. Urowitz, MD, D.D. Gladman, MD, D. Ibañez, MSc, J. Su, MSc, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.

Dominique Ibañez (D)

M.B. Urowitz, MD, D.D. Gladman, MD, D. Ibañez, MSc, J. Su, MSc, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.

Jiandong Su (J)

M.B. Urowitz, MD, D.D. Gladman, MD, D. Ibañez, MSc, J. Su, MSc, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.

Sara Mursleen (S)

S. Mursleen, MSc, A. Sayani, PhD, S. Iczkovitz, MSc, GlaxoSmithKline Inc., Toronto, Ontario, Canada.

Amyn Sayani (A)

S. Mursleen, MSc, A. Sayani, PhD, S. Iczkovitz, MSc, GlaxoSmithKline Inc., Toronto, Ontario, Canada.

Jorge Alfonso Ross Terres (JA)

S. Mursleen, MSc, A. Sayani, PhD, S. Iczkovitz, MSc, GlaxoSmithKline Inc., Toronto, Ontario, Canada.
J.A.R. Terres, MD, GlaxoSmithKline Inc., Toronto, Ontario, Canada, and GlaxoSmithKline Inc., Philadelphia, Pennsylvania, USA.

Sandra Iczkovitz (S)

S. Mursleen, MSc, A. Sayani, PhD, S. Iczkovitz, MSc, GlaxoSmithKline Inc., Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH